Skip to main content

Project ECHO®: Dermatologic Toxicities
with Immune Checkpoint Inhibitors

Telementoring To Manage Immune-related Adverse Events
in Patients Receiving Cancer Immunotherapies

Session 7 — Dermatology

  • CME Information or Content Source:
    Content Derived from a CME Certified Webinar in April 2023
  • Event Details:
    Program provided by Boston University (BU) and Association of Community Cancer Centers (ACCC)
  • Event Sponsor(s):
    This activity is supported by an educational grant from Bristol Myers Squibb

Speakers

Joshua Arbesman,
MD Dermatology Cleveland Clinic Foundation
Cleveland, OH

Laura Wood, RN, MSN, OCN
Oncology Nurse Specialist
Medina, OH

Learning Objectives

At the end of this educational program, participants should be able to:

  • Apply evidence-based practices for the monitoring and management of immune-related adverse events (irAE) in patients receiving cancer immunotherapies
  • Improve coordination and communication with non-oncology specialists and with patients/caregivers to manage irAE in patients receiving cancer immunotherapies
  • Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies

Click here to learn about remaining Project ECHO sessions or to view other available recordings.

Latest